Penile rehabilitation with phosphodiesterase type 5 inhibitors after nerve-sparing radical prostatectomy: are we targeting the right patients?
The results reported in all trials comparing chronic versus on-demand phosphodiesterase type 5 inhibitor use after bilateral nerve-sparing radical prostatectomy may be affected by improper patient selection. Targeting the right patients is the key to optimizing the efficacy of these drugs.